Beste apotheek van Nederland

Heaton J P, Morales A, Adams M A et al. Recovery of erectile
function by the oral administration of apomorphine. Urology
1995;45(2):200-206.
Hellstrom W J. Vardenafil: a new approach to the treatment of
erectile dysfunction. [Review] [37 refs]. Curr Urol Rep
2003;4(6):479-487.
Hirsch I H, Schanne F J, Carsello J et al. Sequential penile
ultrasound monitoring of patients treated with chronic
intracavernous prostaglandin E1. Urology 1995;45(6):1037­
1041.
Hirsch I H, Smith R L, Chancellor M B et al. Use of
intracavernous injection of prostaglandin E1 for neuropathic
erectile dysfunction. Paraplegia 1994;32(10):661-664.
Hollander J B, Gonzalez J, Norman T. Patient satisfaction with
pharmacologic erection program. Urology 1992;39(5):439-441.
Holmes S. Tadalafil: a new treatment for erectile dysfunction.
BJU Int 2003;91(6):466-468.
Hong E K, Lepor H, McCullough A R. Time dependent patient
satisfaction with sildenafil for erectile dysfunction (ED) after
nerve-sparing radical retropubic prostatectomy (RRP). Int J
Impot Res 1999;11(SUPPL. 1):S15-S22.
Hong J H, Ahn T Y. Oral testosterone replacement in Korean
patients with PADAM. Aging Male 2002;5(1):52-56.
Hookes J. Asian Federation of Medicinal Chemistry (AFMC) -
Fifth International Medicinal Chemistry Symposium: 14-17
October 2003, Kyoto, Japan. IDrugs 2003;6(11):1013-1015.
Huang S T, Hsieh M L. Different hemodynamic responses by
color Doppler ultrasonography studies between sildenafil nonresponders
and responders. Asian J Androl 2007;9(1):129-133.
Hubler J, Szanto A, Konyves K. Methylene blue as a means of
treatment for priapism caused by intracavernous injection to
combat erectile dysfunction. International Urology &
Nephrology 2003;35(4):519-521.
Hwang T I, Chen H E, Tsai T F et al. Combined use of androgen
and sildenafil for hypogonadal patients unresponsive to
sildenafil alone. Int J Impot Res 2006;18(4):400-404.
Incrocci L, Hop W C, Slob A K. Visual erotic and vibrotactile
stimulation and intracavernous injection in screening men with
erectile dysfunction: a 3 year experience with 406 cases. Int J
Impot Res 1996;8(4):227-232.
Irwin M B, Kata E J. High attrition rate with intracavernous
injection of prostaglandin E1 for impotency. Urology
1994;43(1):84-87.
Isidori A M, Giannetta E, Gianfrilli D et al. Effects of
testosterone on sexual function in men: results of a metaanalysis.
Clin Endocrinol (Oxf.) 2005;63(4):381-394.
Ismail M, Abbott L, Hirsch I H. Experience with
intracavernous PGE-1 in the treatment of erectile
dysfunction: dose considerations and efficacy. Int J
Impot Res 1997;9(1):39-42.
Israilov S, Niv E, Livne P M et al. Intracavernous
injections for erectile dysfunction in patients with
cardiovascular diseases and failure or
contraindications for sildenafil citrate. Int J Impot Res
2002;14(1):38-43.
Israilov S, Shmuely J, Niv E et al. Evaluation of a
progressive treatment program for erectile dysfunction
in patients with diabetes mellitus. Int J Impot Res
2005;17(5):431-436.
Jackson G. Sildenafil (Viagra): New data, new
confidence in treating erectile dysfunction in the
cardiovascular patient. Int J Clin Pract 2002;56(2):75
Jackson G, Keltai M, Csanady M et al. Hemodynamic
effects of sildenafil citrate and isosorbide mononitrate
in men with coronary artery disease and erectile
dysfunction. Br J Sex Med 2005;2(3):407-414.
Jackson G, Kloner R A, Costigan T M et al. Update on
clinical trials of tadalafil demonstrates no increased
risk of cardiovascular adverse events. Br J Sex Med
2004;1(2):161-167.
Jackson G, Montorsi P, Cheitlin M D. Cardiovascular
safety of sildenafil citrate (Viagra): an updated
perspective. [Review] [52 refs]. Urology 2006;68(3
Suppl):47-60.
Jacobsen F M. Fluoxetine-induced sexual dysfunction
and an open trial of yohimbine.[see comment].
Hillside J Clin Psychiatry 1992;53(4):119-122.
Jain P, Rademaker A W, McVary K T. Testosterone
supplementation for erectile dysfunction: results of a
meta-analysis. Br J Urol 2000;164(2):371-375.
Jarow J P, Burnett A L, Geringer A M. Clinical
efficacy of sildenafil citrate based on etiology and
response to prior treatment.[see comment]. Br J Urol
1999;162(3:Pt 1):t-5.
Jiann B P, Yu C C, Su C C et al. Rechallenge prior
sildenafil nonresponders. Int J Impot Res
2004;16(1):64-68.
Jiann B P, Yu C C, Tsai J Y et al. What to learn about
sildenafil in the treatment of erectile dysfunction from
3-year clinical experience. Int J Impot Res
2003;15(6):412-417.
Jiann B-P, Yu C-C, Su C-C. Impact of introduction of
sildenafil on other treatment modalities for erectile
dysfunction: A study of nationwide and local hospital
sales. Int J Impot Res 2004;16(6):527-530.
D-170